IST5-002 NEW
| Price | $1520 | $1980 | $2500 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-08-29 |
Product Details
| Product Name: IST5-002 | CAS No.: 13484-66-7 |
| Purity: 99.36% | Supply Ability: 10g |
| Release date: 2025/08/29 |
Product Introduction
Bioactivity
| Name | IST5-002 |
| Description | IST5-002 (N6-Benzyladenosine-5'-phosphate) is a selective Stat5a/b inhibitor with anticancer activity that inhibits the transcriptional activity of Stat5a/b and induces apoptosis and death of prostate cancer cells and chronic myelogenous leukemia (CML) cells, which can be used for cancer research. |
| In vitro | IST5-002 is a potent Stat5a/b inhibitor that selectively blocks the transcriptional activity of Stat5a and Stat5b with IC50 values of 1.5 μM (Stat5a) and 3.5 μM (Stat5b), respectively.IST5-002 showed significant inhibitory effects on both Stat5a and Stat5b in a variety of cellular assays. Under different dosage and time conditions, IST5-002 was able to inhibit Bcr-Abl-induced Stat5a/b phosphorylation in K562 cells (0-40 μM, 3 h), Stat5a/b phosphorylation in T47D cells (5-100 μM, 2 h), and Stat5 dimerization and nuclear translocation in PC-3 cells, as well as inhibit the Stat5 target gene and DNA binding in COS-7 cells. In CWR22Rv1 and LNCaP cells, IST5-002 (2-50 μM, 48 h) significantly reduced the expression of Stat5a/b target genes such as Bcl-xL and cyclin D1. In addition, IST5-002 inhibited the growth of human prostate cancer cells by inducing apoptosis at high concentrations (3.1-50 μM, 72 hours) and triggered epithelial cell death in patient-derived prostate cancer samples cultured in vitro (25-100 μM, 7 days). IST5-002 (5 μM, 24-72 h) similarly inhibited Stat5a/b phosphorylation and induced apoptosis in Imatinib-sensitive and -resistant chronic granulocytic leukemia (CML) cells. [1] |
| In vivo | Tumor growth was effectively inhibited in a prostate cancer xenograft model by intraperitoneal injection of 25-100 mg/kg IST5-002 once daily for 10 days. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 100 mg/mL (228.66 mM), Sonication is recommended. DMSO : 100 mg/mL (228.66 mM), Sonication is recommended. |
| Keywords | Stat5b | Stat5a | Apoptosis |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Flubendazole | Cysteamine hydrochloride | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $44.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-09-17 | |
| $1980.00/50mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-10-27 | |
| $66.00/1 PCS |
Amikon Limited
|
2019-02-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY